nitroarginine and Cognition-Disorders

Schizophrenia symptoms can be segregated into positive, negative and cognitive, which exhibit differential sensitivity to drug treatments. Accumulating evidence points to efficacy of alpha7 nicotinic receptor (nAChR) agonists for cognitive deficits in schizophrenia but their activity against positive symptoms is thought to be minimal. The present study examined potential pro-cognitive and antipsychotic activity of the novel selective alpha7 nAChR partial agonist SSR180711 using the latent inhibition (LI) model. LI is the reduced efficacy of a previously non-reinforced stimulus to gain behavioral control when paired with reinforcement, compared with a novel stimulus. Here, no-drug controls displayed LI if non-reinforced pre-exposure to a tone was followed by weak but not strong conditioning (2 vs 5 tone-shock pairings). MK801 (0.05 mg/kg, i.p.) -treated rats as well as rats neonatally treated with nitric oxide synthase inhibitor L-NoArg (10 mg/kg, s.c.) on postnatal days 4-5, persisted in displaying LI with strong conditioning, whereas amphetamine (1 mg/kg) -treated rats failed to show LI with weak conditioning. SSR180711 (0.3, 1, 3 mg/kg, i.p.) was able to alleviate abnormally persistent LI produced by acute MK801 and neonatal L-NoArg; these models are believed to model cognitive aspects of schizophrenia and activity here was consistent with previous findings with alpha7-nAChR agonists. In addition, unexpectedly, SSR180711 (1, 3 mg/kg, i.p.) potentiated LI with strong conditioning in no-drug controls and reversed amphetamine-induced LI disruption, two effects considered predictive of activity against positive symptoms of schizophrenia. These findings suggest that SSR180711 may be beneficial not only for the treatment of cognitive symptoms in schizophrenia, as reported multiple times previously, but also positive symptoms.

Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; Neural Inhibition; Neuroprotective Agents; Nicotinic Agonists; Nitroarginine; Rats; Rats, Wistar; Receptors, Nicotinic; Reinforcement, Psychology; Schizophrenia

NO synthesis disturbances play an important role in the development of neurodegenerative damage in Alzheimer disease. We previously showed that adaptation to intermittent hypobaric hypoxia prevents cognitive disturbances in rats with experimental Alzheimer disease. Here we evaluated the role of NO in cognitive disorders and development of adaptive protection during experimental Alzheimer disease. Adaptation to hypoxia in rats was performed in a hypobaric pressure chamber at a simulated altitude of 4000 m (4 h per day for 14 days). Alzheimer disease was simulated by bilateral injections of a toxic fragment of beta-amyloid (25-35) into n. basalis magnocellularis. For evaluation of the role of NO in the development and prevention of memory disorders, the rats received intraperitoneally either NO-synthase inhibitor N omega-nitro-L-arginin (L-NNA, 20 mg/kg, every other day for 14 days) or NO-donor dinitrosyl iron complex (200 microg/kg daily for 14 days). NO-synthase inhibitor potentiated the damaging effect of beta-amyloid, abolished the protective effect of adaptation to hypoxia, and produced memory disorders in rats similar to those observed during experimental Alzheimer disease. In contrast, the increase in NO level in the body provided by injections of the NO-donor produced a protective effect against memory disorders caused by beta-amyloid similar to that induced by adaptation to hypoxia. We concluded that reduced NO production in the organism plays an important role in the development of cognitive disorders produced by injections of beta-amyloid, while prevention of NO deficit by administration of NO-donors or non-pharmacological stimulation of NO synthesis can provide a protective effect in experimental Alzheimer disease.

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Hypoxia; Iron; Male; Nerve Degeneration; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Nitrogen Oxides; Peptide Fragments; Rats; Rats, Wistar

Phenytoin (PHT) and Valproate (VPA) are known to induce cognitive dysfunction, in terms of long term memory loss. Nitric oxide (NO) on the other hand is said to help in long term potentiation and hence enhance memory. The effects of nitric oxide donor L-arginine (L-Arg) and nitric oxide synthase inhibitor N-W-L-Nitroarginine (L-NOARG) were studied on the cognitive dysfunction, induced by PHT and VPA in normal healthy rats, using the step-through passive avoidance test (PAT). It was observed that combining L-Arg with PHT significantly enhanced long term memory while, combining PHT with L-NOARG decreased it, as compared to PHT alone. When combined with VPA, L-Arg and L-NOARG increased the retention latency as compared to PVA alone but this was not statistically significant. We conclude that the No donor L-Arg is able to increase the difference in LTE in acquisition and retention trials with both PHT and VPA, but with VPA the increase is not statistically significant.

Topics: Animals; Anticonvulsants; Arginine; Cognition Disorders; Enzyme Inhibitors; Female; Male; Memory; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroarginine; Phenytoin; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Valproic Acid